Zogenix closes its $35M second tranche of Series B preferred stock financing

Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee. All existing Zogenix investors including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, and Abingworth Management, as well as new investor, Oxford Finance Corporation, contributed to the total $71 million Series B.

The capital primarily will be used to fully support the launch of SUMAVEL(TM) DosePro(TM) (sumatriptan injection) needle-free delivery system, the company's first product, that will launch in January 2010. Zogenix is also advancing its product pipeline and is actively engaged in efforts to out-license the unique, needle-free DosePro technology to other biopharmaceutical companies.

"Zogenix has developed an innovative product by incorporating a needle-free delivery system, which potentially could also be used for a variety of pharmaceuticals," said Dr. Minorcherhomjee. "The company has a strong management team and board, and is well positioned to capture share in select market segments."

"We are very pleased to welcome Chicago Growth Partners to our investor group and also very fortunate to have the continued support from all of our existing investors," said Roger Hawley, CEO, Zogenix. "Our dedicated Zogenix team is on track with all aspects of our commercial plan, including building our sales force. Zogenix will be fully prepared for our first launch in January. These are exciting times, and I'm proud of our team's accomplishments."

SOURCE Zogenix, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Innovative therapeutic platform for blood-to-brain delivery of antisense oligonucleotide therapy